Jianbo Song

Jianbo Song

Auto-generated profile, based on publicly available information

Jianbo Song

Department of Pharmacy Shanxi Provincial People's Hospital Taiyuan Shanxi China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2020 in Lupus
Verified
Journal Article
Closed access
PDF file
JSJianbo Song
Jianbo Song
LZLiqin Zhao
Liqin Zhao
YLYuanping Li
Yuanping Li
Objective: Lupus nephritis (LN) is one of the serious complications of systemic lupus erythematosus. The aim of this study was to identify core genes and pathways involved in the pathogenesis of LN. Methods: We screened differentially expressed genes (DEGs) in LN patients using mRNA expression profile data from the Gene Expression Omnibus. The functional and pathway enrichment analysis of DEGs was performed utilizing the Database for annotation, Visualization and Integrated Discovery. Target genes with differentially expressed miRNAs (DEMIs) were predicted using the miRTarBase database, and the intersection between these target genes and DEGs was selected to be studied further. Results: In total, 107 common DEGs (CDEGs) were identified from the Tub_LN group and Glom_LN group, and 66 DEMIs were identified. Fifty-three hub genes and two significant modules were identified from the protein–protein interaction (PPI) network, and a miRNA–mRNA network was constructed. The CDEGs, module genes in the PPI network and genes intersecting with the CDEGs and target genes of DEMIs were all associated with the PI3K-Akt signalling pathway. Conclusion: In summary, this study reveals some crucial genes and pathways potentially involving in the pathogenesis of LN. These findings provide a new insight for the research and treatment of LN.

10 September 2026 in Phytotherapy Research
Verified
Journal Article
Open access
XWXiao Wei
Xiao Wei
HWHong‐Ping Wen
Hong‐Ping Wen
JSJian‐Bo Song
Jian‐Bo Song
JXJinfang Xu
Jinfang Xu
HGHong‐Rui Guo
Hong‐Rui Guo
Colorectal cancer (CRC) remains a leading cause of cancer mortality, necessitating novel therapeutic strategies. Schisandrin C (SinC), a bioactive lignan from Schisandra chinensis , exhibits diverse pharmacological activities, but its anti‐CRC mechanisms are poorly understood. This study investigated the anti‐CRC mechanism of SinC, focusing on PPARγ‐mediated ferroptosis and macrophage polarization. Network pharmacology predicted core targets and pathways. Direct SinC‐PPARγ binding was confirmed by molecular docking, CETSA, and luciferase reporter assays. In HCT116 and LoVo cells, proliferation, migration, and ferroptosis were evaluated, with mechanistic validation using a PPARγ agonist, antagonist, and shRNA. M1/M2 markers in RAW264.7 macrophages were detected. In an AOM/DSS‐induced CAC mouse model, ferroptosis and macrophage polarization were assessed by Prussian blue staining, immunohistochemistry, and Western blotting. SinC directly bound and activated PPARγ, concentration‐dependently inhibiting CRC cell proliferation, migration, and colony formation while inducing ferroptosis—effects reversed by liproxstatin. Mechanistically, SinC activated PPARγ, suppressed JAK2/STAT3 signaling, and downregulated SLC7A11/GPX4, effects enhanced by a PPARγ agonist and abolished by PPARγ antagonist or shRNA. SinC upregulated M1 markers and pro‐inflammatory cytokines, with a predominant M1‐associated activation pattern. In CAC model, SinC improved survival, inhibited tumor growth, alleviated colonic pathology, exhibited biochemical features consistent with ferroptosis, and increased intratumoral CD86 + cell infiltration. SinC directly binds and activates PPARγ transcriptional activity, inducing ferroptosis in CRC cells via the PPARγ‐JAK2/STAT3‐SLC7A11/GPX4 axis while concurrently promoting M1 macrophage polarization, exerting a dual antitumor effect. These findings support SinC as a promising therapeutic candidate for CRC.